Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-UC: Immunotherapy Combinations in Urothelial Carcinoma
NCT03869190Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, enfortumab vedotin, niraparib, magrolimab, tiragolumab and 3 more in urothelial carcinoma (UC) and bladder cancer (16 cohorts), sponsored by Roche. Primary endpoints: Objective Response Rate up to 61.5 months and Pathological Complete Response up to 17.8 months. Started Jun 2019; status: terminated.
02
Drugs
atezolizumabenfortumab vedotinniraparibmagrolimabtiragolumab
03
Conditions
urothelial carcinoma (UC)bladder cancer
Beyond the preview
Go deeper on NCT03869190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869190.